• A
  • ABL1
    BCR-ABL1 Fusion, BCR-ABL1 Fusion and T315I, BCR-ABL1 fusion AND T315I AND E355G, NUP214-ABL1 fusion, G250H, Q252H, Y253H, E255K, E255V, V299L, T315A, T315I, F317C, F317I, F317L, F317V, A337V, F359C, F359I, F359V, E459K, P465S, F486S
  • AKT1
    LAMTOR1-AKT1 fusion, Oncogenic mutation, Oncogenic mutations, E17K
  • AKT2
    Oncogenic mutations
  • AKT3
    Oncogenic mutations
  • ALK
    CAD-ALK fusion, EML4-ALK Fusion, Fusion, Fusion AND Amplification, Fusions, NPM-ALK fusion, RANBP2-ALK Fusion, SPECC1L-ALK fusion, STRN-ALK fusion, VCL-ALK fusion, VKORC1L1-ALK fusion, Oncogenic mutation, Oncogenic mutations, Exon 2-17 deletion, Exon 2–3 deletion, Amplification, A348D, F856S, L1122V, G1128A, E1129V, I1151ins, T1151, T1151K, T1151M, T1151R, T1151_L1152insT, T1151ins, T1151insT, L1152P, L1152R, L1152V, C1156T, C1156Y, C1156Y and G1202R, D1160H, I1171, I1171N, I1171N and D1203N, I1171N and L1198F, I1171S, I1171T, I1171ins, F1174, F1174C, F1174L, F1174S, F1174V, V1180L, R1192P, L1196M, L1196M and G1202R, L1196M and L1198F, L1196Q, F1197M, L1198F, L1198F and C1156Y, L1198F and G1202R, L1198P, G1202R, G1202R and F1174L, G1202R and G1269A, G1202R and L1196M, G1202R and L1198F, G1202R and T1151M, G1202del, D1203E, D1203N, D1203N and E1210K, S1206C, S1206F, S1206R, S1206Y, E1210K, E1210K and D1203N, E1210K and S1206C, F1245C, F1245L, F1245V, F1245Y, G1269A, G1269S, S1269S, R1275Q, D1276_R1279, Y1278S, E1408V
  • APC
    Oncogenic mutations, Loss-of-function mutations
  • APC+PIK3CA
    APC:Oncogenic mutations AND PIK3CA:Oncogenic mutations
  • AR
    Oncogenic mutations, Amplification, Amplifications, L702H, L702H and H875Y, L702H and T878A, L702H and W742C and T878A, V716M, V731M, W742C, W742C and T878A, W742L, H875Q, H875Q and T919S, H875Y, H875Y and T878A, F877L, F877L and T878A, T878A, T878A and D891H, T878A and S889G, T878S, D880E, L882I, S889G, D891H, E894K, M896T, M896V, E898G, T919S, AR-FL, AR-V7, Alteration, Ligand-binding domain mutation, Overexpression, Protein expression, Wildtype
  • AR+ESR1 (ER)
    AR:Protein expression and ESR1:Protein expression
  • ARAF
    Oncogenic mutations, S214C, P216A, K336M, K336M and G387D, R362H and G387D, G377R, G387D, G387R, G387S, P462L, Overexpression
  • ARID1A
    Oncogenic mutation, Oncogenic mutations, Oncogenic mutations AND Loss of protein expression, Oncogenic mutations AND NOT Loss of protein expression, Loss-of-function mutations, Truncating mutations
  • ARID1B
    Oncogenic mutations
  • ARID2
    Loss of protein expression, Loss-of-function mutations
  • ATM
    Oncogenic mutation, Oncogenic mutations, Oncogenic mutations (germline), S1905Ifs*25, Loss of protein expression, Loss-of-function mutations, Loss-of-protein expression, Protein expression, Truncating mutations
  • ATM+TP53
    ATM:Oncogenic mutations and NOT TP53:Oncogenic mutations
  • ATR
    Oncogenic mutation, Oncogenic mutations, Overexpression
  • ATRX
    Oncogenic mutation, Oncogenic mutations, Loss-of-function mutations
  • AURKA
    Amplification
  • B
  • B2M
    deletion, Loss of protein expression, Loss-of-function mutations
  • BAP1
    Oncogenic mutations, deletion, Loss of protein expression, Loss-of-function mutations
  • BARD1
    Oncogenic mutations, Oncogenic mutations (germline), Loss-of-function mutations
  • BCL2
    Amplification, G101V, D103Y, A113G, Overexpression
  • BCL2L1
    Amplification
  • BCL2L11
    deletion
  • BCL6
    Protein expression
  • BRAF
    AGAP3-BRAF fusion, AGK-BRAF fusion, AKAP9-BRAF fusion, BCAP29-BRAF fusion, CUL1-BRAF fusion, FKBP15-BRAF fusion, Fusion, Fusions, KIAA1549-BRAF fusion, LUC7L2-BRAF fusion, MBNL2-BRAF fusion, PJA2-BRAF fusion, SKAP2-BRAF fusion, SND1-BRAF fusion, TARDBP-BRAF fusion, ZC3HAV1-BRAF fusion, Class I mutation, Class I mutations, Class II mutation, Class II mutations, Class III mutation, Class III mutations, Oncogenic mutation, Oncogenic mutations, Oncogenic mutations AND NOT V600, Exon 12 deletion, Amplification, V600E and Amplification, V226M, F247L, D287, D287H, I326V, E375D, A400V, V459, V459L, G464E, G464V, G466, G466A, G466E, G466V, S467, S467L, G469A, G469R, G469V, T470R, L485F, L485_P490del, L485_P490delinsF, L485_P490delinsY, L485delinsFS, N486_P490del, N486_T491del, V487_P492>, V487_P492del, V487_P492delinsA, L505H, Y519F, Q524L, L525R, R558Q, G569R, N581, N581I, N581S, N581T, N581Y, D594, D594A, D594G, D594H, D594N, F595, F595L, G596, G596C, G596D, G596R, L597, L597Q, L597R, L597V, A598_T599insV, T599_V600TinsT, T599_V600insT, V600, V600E, V600E and L514V, V600K, V600M, V600R, K601, K601E, K601N, K601T, I617V, A, BRAF-CREB3L2 rearrangement
  • BRAF+EGFR
    EGFR:exon 19 deletion and BRAF:V600E
  • BRAF+KRAS
    BRAF:V600E AND KRAS:Oncogenic mutations, BRAF:V600E AND KRAS:A146, BRAF:V600E AND KRAS:G12, BRAF:V600E AND KRAS:G12D, BRAF:V600E AND KRAS:G13, BRAF:V600E AND KRAS:K117, BRAF:V600E AND KRAS:Q61, BRAF:V600E AND KRAS:Q61R
  • BRAF+MAP2K1
    BRAF:V600E AND MAP2K1:Oncogenic mutations, BRAF:V600E AND MAP2K1:F53, BRAF:V600E AND MAP2K1:K57, BRAF:V600E AND MAP2K1:K57N
  • BRAF+MET
    Amplification, BRAF:V600E AND MET:amplification
  • BRAF+NRAS
    BRAF:V600E AND NRAS:Oncogenic mutations, BRAF:V600E AND NRAS:G12, BRAF:V600E AND NRAS:G13, BRAF:V600E AND NRAS:Q61, BRAF:V600E AND NRAS:Q61R
  • BRAF+PTEN
    BRAF:V600E AND PTEN:Oncogenic mutations
  • BRCA1
    Oncogenic mutations, Oncogenic mutations (germline), Oncogenic mutations AND NOT Oncogenic mutations (germline), M1I, M1V, C61G, C64Y, R71G, R71K, S1253fs*10, R1495M, E1559K, D1692H, D1692N, R1699W, A1708E, G1788V, 9435_9436delGT, Loss of protein expression, Loss-of-function mutations, Promoter methylation, Reversion mutations
  • BRCA1+BRCA2
    NOT BRCA1:Oncogenic mutations (germline) and NOT BRCA2:Oncogenic mutations (germline), NOT BRCA1:Oncogenic mutations and NOT BRCA2:Oncogenic mutations
  • BRCA1+ERBB2 (HER2)
    BRCA1:Oncogenic mutation and NOT ERBB2:Overexpression and NOT ERBB2:Amplification
  • BRCA2
    Oncogenic mutation, Oncogenic mutations, Oncogenic mutations (germline), Oncogenic mutations AND NOT Oncogenic mutations (germline), Deletions, M1I, M1R, V159M, V211I, V211L, R2336H, R2336P, Loss-of-function mutations, Promoter methylation, Reversion mutations
  • BRCA2+PTEN
    BRCA2:deletion and PTEN:deletion
  • BRD3
    BRD3-NUTM1 fusion
  • BRD4
    BRD4-NUTM1 fusion, Fusion, Oncogenic mutations
  • BRD7
    Loss-of-function mutations
  • BRIP1
    Oncogenic mutation, Oncogenic mutations, Q554Hfs*35, Loss-of-function mutations
  • C
  • CALB1
    High mRNA expression
  • CAMTA1
    TAZ-CAMTA1 fusion
  • CBL
    Y371H, C384R
  • CCL11
    Serum level high
  • CCND1
    Amplification, Overexpression
  • CCND2
    Amplification
  • CCND3
    Amplification
  • CCNE1
    Amplification, Overexpression, mRNA expression
  • CCR4
    Protein expression
  • CD123
    Overexpression
  • CD19
    Overexpression, Protein expression
  • CD20
    Protein expression
  • CD274 (PD-L1)
    Amplification, Loss of protein expression, Protein expression
  • CD274+EGFR+ALK
    CD274:Protein expression and NOT EGFR:Oncogenic mutations and NOT ALK:fusion
  • CD276 (B7-H3)
    Protein expression
  • CD33
    Protein expression
  • CD38
    Overexpression
  • CD79B
    Protein expression
  • CD8
    High
  • CDH1
    Loss-of-function mutations
  • CDH6
    Protein expression
  • CDK12
    Oncogenic mutation, Oncogenic mutations, Kinase domain mutations, Loss of protein expression, Loss-of-function mutations, Protein expression, Rearrangement, Truncating mutations
  • CDK4
    Oncogenic mutations, Amplification, Amplification and NOT overexpression, Overexpression
  • CDK6
    Oncogenic mutations, Amplification, Overexpression
  • CDKN2A
    Oncogenic mutation, Oncogenic mutations, Deletions, deletion, Loss of protein expression, Loss-of-function mutations, Truncating mutations
  • CDKN2A+MTAP
    CDKN2A:deletion and MTAP:deletion
  • CEACAM5
    Overexpression, Protein expression
  • CHEK1
    Oncogenic mutations, Loss-of-function mutations, Overexpression
  • CHEK2
    Oncogenic mutation, Oncogenic mutations
  • CLDN18
    Low protein expression, Overexpression, Protein expression
  • CLDN18+ERBB2 (HER2)
    CLDN18:Protein expression AND NOT ERBB2:Amplification, CLDN18:Protein expression AND NOT ERBB2:Overexpression
  • CLDN6
    Protein expression
  • CRKL
    Amplification, Overexpression
  • CSF1
    Fusion, Overexpression, Rearrangement
  • CTAG1B
    Overexpression, Protein expression
  • CTNNB1
    Oncogenic mutations, T41A, S45F, Gain-of-function mutations
  • CTNNB1+KIT
    CTNNB1:S33C and KIT:L576P
  • CXCL13
    Overexpression
  • CXCR4
    S338X
  • Chromosome
    3p25.3 copy number gain
  • Consensus molecular subtype
    CMS2, CMS3, CMS4
  • D
  • DAXX
    Oncogenic mutation, Overexpression
  • DHFR
    Amplification
  • DLK1
    Protein expression
  • DLL3
    High expression, Protein expression
  • DNMT3A
    Oncogenic mutations, Deletions, Loss-of-function mutations, Truncating mutations
  • E
  • EGFR
    EGFR-PURB fusion, EGFR-RAD51 fusion, EGFR-SEPT14 Fusion, KIF5B-EGFR fusion, Amplification AND NOT Oncogenic mutations, Amplification and NOT Oncogenic mutation, Oncogenic mutation, Oncogenic mutation and NOT Exon 19 deletion and NOT L858R, Oncogenic mutations, Exon 18 deletion, Exon 18 mutation, Amplification and Exon 19 deletion, EGFR:exon 19 deletion and BRAF:V600E, Exon 19 deletion, Exon 19 deletion and C797S, Exon 19 deletion and G724S, Exon 19 deletion and G796S, Exon 19 deletion and L718Q, Exon 19 deletion and L718V, Exon 19 deletion and L792F, Exon 19 deletion and L792H, Exon 19 deletion and T790M, Exon 19 deletion and T790M and C797S, Exon 19 deletion and T790M and G724S, Exon 19 deletion and T790M and L718V, Exon 19 deletion and T790M and L792H, Exon 19 deletion and T854I, Exon 19 deletion and amplification, Exon 19 deletions, Exon 19 indels, Exon 19 insertion, Exon 20 insertion, Exon 20 insertion and T790M and C797S, Exon 20 insertion except A763_Y764insFQEA, Exon 20 insertion mutations, Exon 20 insertions, Exon 20 mutation, Exon 21 mutation, Exon 21 mutation and amplification, Amplification, Amplification AND G598V, Amplification and L858R, L858R and amplification, G63R, E114K, R165Q, R222C, T263P, A289D, A289V, R451C, S464L, G465R, K467T, I491M, S492R, P596L, G598V, V659E, K708R, E709A, E709A and G719S, E709K, E709K and G719S, E709K and L858R, E709_T710delinsD, L718Q, L718Q and T790M, L718V, G719, G719A, G719A and L861Q, G719A and R776C, G719A and T790M, G719S, G719S and E709K, G719S and R776H, G719S and T790M, G719Y, S720P, G724S, G724S and R776H, G724S and T790M, T725M, I740_K745dupIPVAIK, I740dupIPVAK, L747P, L747S, L747_A750delinsP, L747_K754delInsATSPE, L747_P753delinsS, L747_T751del and D837T, T751_I759delinsS, S752_I759del, K754E, K757R, D761N, D761Y, A763_Y764insFQEA, A763_Y764insLQEA, A763insFQEA, A767_V769dup, A767insASV, S768I, S768I and T790M, S768I and V769L, S768I and V774M, S768_D770dup, S768dupSVD, S768dupSVD and V769M, V769L, V769_D770insASV, V769_D770insGG, V769insASV, D770_N771insG, D770_N771insGD, D770_N771insGL, D770_N771insSVD, D770delinsDV, D770delinsGY, D770insG, D770insNPG, D770insSVD, D770insY, N771_H773dup, N771_P772insH, N771_P772insSVDN, N771delinsKH, N771dupN, N771dupN and G724S, N771insH, P772_H773insGNP, P772_H773insPNP, P772dupDNP, H773L and V774M, H773Y, H773_V774insAH, H773_V774insH, H773_V774insNPH, H773_V774insPHPH, H773insH, H773insNPH, V774M, V774_C775insHV, R776C, R776H, F784F, S784F, T790M, T790M and C797S and T790M-C797S trans-allelic conformation, T790M and G796R, T790M and L792H, L792, L792H, C797G, C797S, C797S and T790M, K806E, S811F, N826Y, L833F, L833V, L833V and H835L, H835L, N842S, V843I, T847I, V851I, T854A, L858R, L858R and A871E, L858R and C797G, L858R and C797S, L858R and G724S, L858R and G873E, L858R and L718Q, L858R and L718V, L858R and L792F, L858R and L792H, L858R and S784F, L858R and T790M, L858R and T790M and C797S, L858R and T790M and L718Q, L858R and T790M and L718V, L858R and T790M and L792H, L858R and T790M and V843I, L858R and V834L, L861Q, L861R, Kinase domain duplication, Kinase domain duplication AND T790M, Kinase domain duplication AND T790M AND C797S, Overexpression, Protein expression, activating mutations, ectodomain mutation, vIII, vIII AND D247Y
  • EGFR+ALK
    EGFR:Oncogenic mutations and ALK:fusion
  • EGFR+BRAF
    EGFR:Oncogenic mutations and BRAF:V600E
  • EGFR+CD274
    CD274:Protein expression and EGFR:Oncogenic mutations
  • EGFR+EGFR
    Amplification and Exon 19 deletion, C797S and Exon 19 deletion, E709K and Exon 19 deletion, G724S and Exon 19 deletion, G796S and Exon 19 deletion, L718 and Exon 19 deletion, L792H and Exon 19 deletion, Amplification and L858R, E709K and L858R, L718 and L858R, G724S and L858R, L792H and L858R, G796S and L858R, C797S and L858R, EGFR:T790M and EGFR:C797S and EGFR:T790M-C797S cis-allelic conformation
  • EGFR+ERBB2 (HER2)
    EGFR:Oncogenic mutations and ERBB2:amplification, EGFR:Exon 19 deletion and ERBB2:Amplification
  • EGFR+ERBB3
    EGFR:Protein expression AND ERBB3:Protein expression
  • EGFR+ERRFI1
    EGFR:low expression AND ERRFI1:Oncogenic mutations, EGFR:overexpression AND ERRFI1:Oncogenic mutations
  • EGFR+MET
    EGFR:Oncogenic mutation AND MET:amplification AND MET:D1228, EGFR:Oncogenic mutation AND MET:amplification AND MET:D1230, EGFR:Oncogenic mutations and MET:amplification, EGFR:Oncogenic mutations and MET:amplification and NOT EGFR:T790M, MET:Alteration and EGFR:Oncogenic mutations, MET:overexpression AND NOT EGFR:oncogenic mutation, EGFR:L858R and MET:exon 14 skipping mutation, EGFR:Exon 19 deletion and MET:amplification, EGFR:Exon 19 deletion and MET:exon 14 skipping mutation, MET:amplification and EGFR:exon 19 deletion, EGFR:L858R and MET:amplification, EGFR:T790M and MET:amplification, MET:amplification and EGFR:L858R
  • EGFR+MET+ALK
    EGFR:Oncogenic mutation AND MET:amplification AND EML4-ALK fusion
  • EGFR+MET+BRAF
    EGFR:Oncogenic mutation AND MET:amplification AND BRAF:Oncogenic mutation
  • EGFR+MET+KRAS
    EGFR:Oncogenic mutation AND MET:amplification AND KRAS:Oncogenic mutation
  • EGFR+RB1
    EGFR:Oncogenic mutations and RB1:Oncogenic mutations
  • EGFR+RBM10
    EGFR:Oncogenic mutations and RBM10:Loss-of-function mutations
  • EGFR+RET
    EGFR:Exon 19 deletion and EGFR:T790M and RET:ANK3-RET fusion, EGFR:Oncogenic mutations and RET:fusion
  • EGFR+ROS1
    EGFR:Oncogenic mutations and ROS1:fusion, GOPC-ROS1 Fusion
  • EGFR+TP53
    EGFR:Oncogenic mutations and TP53:Oncogenic mutations
  • EIF1AX
    G6_splice, G8V, G9, K10N, R13, G15D, A113_splice, N-terminal tail mutation
  • EIF1AX+NRAS
    EIF1AX:A113splice and NRAS:Oncogenic mutations, EIF1AX:Oncogenic mutations and NRAS:Oncogenic mutations
  • EIF4EBP1
    Protein expression
  • EMSY
    Amplification, Overexpression
  • EPAS1
    Oncogenic mutations (germline), A530E (germline)
  • EPHA7
    Oncogenic mutations
  • ERBB2 (HER2)
    ERBB2-GRB7 fusion, Fusions, MDK-ERBB2 fusion, ZNF207-ERBB2 fusion, ERBB2:Oncogenic mutations and NOT ERBB2:amplification, Oncogenic mutation, Oncogenic mutations, Overexpression AND NOT Oncogenic mutations, Protein expression AND NOT Oncogenic mutations, Exon 16 skipping mutation, Exon 20 insertion, Exon 20 insertion except G778ins, Exon 20 insertion mutation, Exon 20 mutation, Exon 21 mutation, Amplification, Amplification and A775_G776insTVMA, Amplification and D769Y, Amplification and L313I, Amplification and L755S, Amplification and NOT overexpression, Amplification and R456C, Amplification and S310F, Amplification and V777L, ERBB2:amplification, ERBB2:amplification and KRAS:G12D, Low protein expression and NOT Amplification, NOT Amplification and NOT Overexpression, Protein expression AND Amplification, Protein expression AND Amplification AND NOT Overexpression, Protein expression NOT amplification, Protein expression and NOT Amplification, Q57R, p95 expression, S113F, R188C, S250C, E265K, D277H and S310F, D277Y, G309A, G309E, S310, S310A, S310F, S310Y, E321G, S335C, E395K, L403V, R487W, P489L, S653C, V659D, V659E, G660D, G660D and S310F, G660R, Q678Q, R678Q, D679H, V697L, Q709, D742N, K753E, L755A, L755F, L755M, L755P, L755S, L755_759del, L755_T759del, G766V, I767M, I767N, A769H, D769H, D769N, D769Y, V773M, M774dup, A775_G776insTVMA, A775_G776insYVMA (Y772_A775dup), A775_Y776insYVMA, A775_Y776insYVMA (Y772_A775dup), G776, G776C, G776R, G776S, G776V, G776_V777delinsCVC, G776_V777delinsCVCS310Y, G776_V777delinsLC, G776_V777delinsVV, G776delinsLC, G776delinsVC, G776delinsVG, G776ins, V777L, V777M, V777_G778insGC, V777_G778insV, G778_S779insG, G778_S779insLPS, G778ins, G778insCPG, S779_P780insVGS, S779ins, P780_Y781insGSP (G778_P780dup), P780ins, L785F, L786V, T798I, T798M, C805S, G815R, L841V, V842I, N857S, T862A, L869R, L869R and T798I, R896C, D962N, L1157R, P1199S, P1199T, Alteration, Extracellular domain mutation, Extracellular domain mutations, Intracellular domain, Juxtamembrane domain mutation, Kinase domain mutation, Low protein expression, Low-protein expression, No protein expression, Overexpression, Protein expression, Transmembrane domain, Transmembrane domain mutation, Tyrosine kinase domain mutation, Tyrosine kinase domain mutations, transmembrane domain mutations
  • ERBB2 (HER2)+CD274
    CD274:Protein expression and NOT ERBB2:Amplification and NOT ERBB2:Overexpression
  • ERBB2 (HER2)+ERBB3
    ERBB2:Oncogenic mutation and ERBB3:E928G, ERBB2:L755S and ERBB3:E928G, ERBB2:L869R and ERBB3:E928G, ERBB2:S310F and ERBB3:E928G, ERBB2:V777L and ERBB3:E928G
  • ERBB2 (HER2)+ESR1 (ER)
    ESR1:Protein expression and NOT ERBB2:amplification and NOT ERBB2:overexpression
  • ERBB2 (HER2)+KRAS
    ERBB2:Amplification AND KRAS:Oncogenic mutations, ERBB2:Amplification and ERBB2:Protein expression and NOT KRAS:Oncogenic mutations and NOT BRAF:V600E, ERBB2:Oncogenic mutations AND KRAS:Oncogenic mutations, ERBB2:Overexpression AND KRAS:Oncogenic mutation, ERBB2:Overexpression AND KRAS:Oncogenic mutations, ERBB2:Overexpression and NOT KRAS:Oncogenic mutations and NOT BRAF:V600E, ERBB2:Protein expression AND KRAS:Oncogenic mutation, ERBB2:amplification and KRAS:G12, ERBB2:amplification and KRAS:G12D
  • ERBB2 (HER2)+PTEN
    ERBB2:Oncogenic mutations and PTEN:Deletion, ERBB2:Oncogenic mutations and PTEN:Loss of protein expression, ERBB2:Oncogenic mutations and PTEN:Loss-of-function mutations, ERBB2:Oncogenic mutations and PTEN:Oncogenic mutations
  • ERBB3
    Oncogenic mutation, Oncogenic mutations, Amplification, F94L, R103G, V104L, V104M, A232V, G248R, P262H, G284R, D297Y, T355A, T355I, Y789fs, Q809R, S846I, S864I, Q865H, E928G, E1261A, Extracellular domain mutations, Low protein expression, Overexpression, Protein expression, Truncating mutations
  • ERBB4
    Oncogenic mutations
  • ERCC1
    Oncogenic mutations, Loss of protein expression
  • ERCC2
    Oncogenic mutations
  • ERRFI1
    deletion, E384X, Loss-of-function mutations
  • ESR1 (ER)
    ESR1-ARNT2 fusion, ESR1-PCDH11X fusion, ESR1-SOX9 fusion, ESR1-YAP1 fusion, Fusion, Oncogenic mutations, D351Y, E380, E380Q, E380Q and F404L, V392I, F404I, F404L, F404V, V422del, S463P, M528I, V534E, P535H, L536, L536H, L536P, L536Q, L536R, Y537, Y537C, Y537D, Y537N, Y537S, D538, D538G, D538G and F404L, Protein expression
  • ESR1 (ER)+CCNE1
    ESR1:Protein expression and CCNE1:Amplification
  • ESR1 (ER)+ERBB2 (HER2)
    ESR1:Protein expression and ESR1:oncogenic mutations and NOT ERBB2:amplification and NOT ERBB2:overexpression, ESR1:Protein expression and ERBB2:Low protein expression and NOT ERBB2:amplification, ESR1:Protein expression and ERBB2:Protein expression and NOT ERBB2:amplification, ESR1:Protein expression and NOT ERBB2:amplification and NOT ERBB2:overexpression, ESR1:D538, ESR1:Protein expression and ERBB2:Ultra-low protein expression, ESR1:Y537, NOT ESR1:protein expression and NOT ERBB2:amplified, NOT ESR1:protein expression and NOT ERBB2:overexpression
  • ESR1 (ER)+ERBB2 (HER2)+PIK3CA
    ESR1:Protein expression and NOT ERBB2:amplification and NOT ERBB2:overexpression and PIK3CA:Oncogenic mutations
  • ESR1 (ER)+MDM2
    ESR1:Protein expression AND MDM2:Amplification
  • ESR1 (ER)+PIK3CA
    ESR1:protein expression and PIK3CA:oncogenic mutation
  • ESR1 (ER)+TP53
    ESR1:Protein expression AND TP53:Oncogenic mutations
  • EZH2
    Oncogenic mutations, Y641C, Y641F, Y641H, Y641N, Y641S, Y646, Y646C, Y646F, Y646H, Y646N, Y646S, Y666N, A677G, A682G, A687V, A692V
  • F
  • F3
    Protein expression
  • FAM175A
    Loss-of-function mutations
  • FANCA
    S1088F, Loss-of-function mutations
  • FANCC
    Oncogenic mutations, Loss of protein expression
  • FANCD2
    Oncogenic mutations, Oncogenic mutations (germline), Loss-of-function mutations
  • FANCG
    Oncogenic mutations
  • FANCI
    Oncogenic mutations
  • FANCL
    Oncogenic mutations
  • FANCM
    Oncogenic mutations
  • FAT1
    Loss-of-function mutations
  • FBXW7
    Oncogenic mutation, Oncogenic mutations, deletion, L403fs*34, R465C, R479Q, R505, R505C, R505H, G579W, R658Q, S668fs*39, Loss-of-function mutations
  • FGF19
    Amplification, Overexpression
  • FGFR1
    FGFR1-PLAG1 fusion, FGFR1-TACC1 fusion, Fusion, Fusions, Oncogenic mutations, Oncogenic mutations and NOT V561, Amplification, N546D, N546K, V559L, V559M, V561M, M563T, N564K, K656E, Alteration, High mRNA expression, Overexpression, Rearrangement
  • FGFR2
    BCR-FGFR2 fusion AND N550K, BCR-FGFR2 fusion AND V565F, BCR-FGFR2 fusion AND V565I, FGFR1-WDHD1 fusion, FGFR2-ACLY fusion, FGFR2-ACOT11 fusion, FGFR2-AFF4 fusion, FGFR2-AHCYL1 fusion, FGFR2-ARHGAP22 fusion, FGFR2-ARHGAP24 fusion, FGFR2-ATAD2 fusion, FGFR2-ATE1 fusion, FGFR2-ATF2 fusion, FGFR2-BICC1 fusion, FGFR2-BICD1 fusion, FGFR2-CASP7 fusion, FGFR2-CCDC158 fusion, FGFR2-CCDC170 fusion, FGFR2-CCDC6 fusion, FGFR2-CEP128 fusion, FGFR2-CLIP1 fusion, FGFR2-COL16A1 fusion, FGFR2-CROCC fusion, FGFR2-CTNNA3 fusion, FGFR2-DBP fusion, FGFR2-DNAJC12 fusion, FGFR2-EEA1 fusion, FGFR2-EIF4ENIF1 fusion, FGFR2-FILIP1 fusion, FGFR2-FOXP1 fusion, FGFR2-GAB2 fusion, FGFR2-GOPC fusion, FGFR2-INSC fusion, FGFR2-KCTD1 fusion, FGFR2-KIAA1217 fusion, FGFR2-KIAA1598 fusion, FGFR2-LAMC1 fusion, FGFR2-MACF1 fusion, FGFR2-MATR3 fusion, FGFR2-MCU fusion, FGFR2-MRVI1 fusion, FGFR2-NEDD4L fusion, FGFR2-NOL4 fusion, FGFR2-NRAP fusion, FGFR2-NRBF2 fusion, FGFR2-OPTN fusion, FGFR2-PAH fusion, FGFR2-PAWR fusion, FGFR2-POC1B fusion, FGFR2-PXN fusion, FGFR2-RABGAP1L fusion, FGFR2-RASSF4 fusion, FGFR2-RBM20 fusion, FGFR2-RPAP3 fusion, FGFR2-SFI1 fusion, FGFR2-SHROOM3 fusion, FGFR2-SLMAP fusion, FGFR2-SOGA1 fusion, FGFR2-SPICE1 fusion, FGFR2-STRN4 fusion, FGFR2-TACC1 fusion, FGFR2-TACC2 fusion, FGFR2-TFEC fusion, FGFR2-TRIM8 fusion, FGFR2-TTC28 fusion, FGFR2-TXLNB fusion, FGFR2-USH2A fusion, FGFR2-VCL fusion, FGFR2-WAC fusion, FGFR2-WDHD1 fusion, FGFR2-ZMYM4 fusion, FTFR2-TRIM8 fusion, Fusion, Fusion and E566A, Fusion and E566G, Fusion and K642I, Fusion and K642R, Fusion and K660M, Fusion and N550D, Fusion and N550K, Fusion and V563L, Fusion and V565I, Fusions, Oncogenic mutations, Oncogenic mutations and NOT Amplification, Oncogenic mutations and NOT V564, Exon 18 truncating mutations, Amplification, FGFR2-E1-17AND Amplification, Extracellular domain deletion, H167_N173del, S252W, C287R, W290C, I291_Y308del, K310R, Y375C, C382R, C383R, V395D, C492, K505E, M537I, N549D, N549F, N549H, N549K, N549S, N550, N550D, N550H, N550K, L552F, V563I, V563L, V564F, V564I, V564L, V564M, E565A, V565, V565I, V565L, E566A, E566G, K569M, L617M, L617V, L618F, L618M, L618V, K641N, K641R, K642I, K642R, L642R, N653S, K659M, K659N, K660M, K660N, R664W, Y674*, R678H, Y678*, L681fs*, P686*, S687fs*, S694*, FGFR2 C382R, FGFR2 I291_Y308del, FGFR2 W290C, FGFR2 Y375C, FGFR2 rearrangement, FGFR2-E18, FGFR2-E18-C2, FGFR2-E18-C3, FGFR2-E18-C4, FGFR2-I17, FGFR2-IIIb:Overexpression, FGFR2-USP33, FGFR2-delE18, FGFR2b:Overexpression, Overexpression, Rearrangements, Splice mutations, Truncating mutations
  • FGFR2
    C382R
  • FGFR3
    FGFR1-TACC3:fusion, FGFR1-TACC3:fusion_V1, FGFR1-TACC3:fusion_V3, FGFR3 fusions, FGFR3-BAIAP2L1 fusion, FGFR3-TACC3 fusion, FGFR3-TACC3_V1 fusion, FGFR3-TACC3_V3 fusion, Fusion, Fusions, High mRNA expression and FGFR3-TACC3 fusion, High mRNA expression and Oncogenic mutation, Oncogenic mutations, Oncogenic mutations and NOT V565 and NOT V550, Amplification, R248C, S249C, G370C, S371C, Y373C, Y375C, F386L, A393E, V443, M528I, N540K, N540S, V553M, V555G, V555K, V555L, V555M, L608V, K650E, K650M, S764fs*6, FGFR3 Y373C, High mRNA expression, High mRNA expression and G370C, High mRNA expression and R248C, High mRNA expression and S249C, High mRNA expression and Y373C, Overexpression
  • FGFR4
    V550E, V550L
  • FH
    Oncogenic mutations, Loss-of-function mutations (germline)
  • FLCN
    Loss-of-function mutations
  • FLI1
    EWSR1-FLI1 Fusion
  • FLT3
    Oncogenic mutations, Amplification, F691L, D835, D835V, D835Y, I836, Y842C, Internal tandem duplication, Kinase domain mutation
  • FOLR1 (Folate receptor alpha)
    Overexpression, Protein expression
  • FRS2
    Amplification
  • G
  • GLI1
    Overexpression
  • GLI2
    Overexpression
  • GNA11
    Oncogenic mutations, Q209L
  • GNAQ
    Oncogenic mutations
  • GNAS
    Oncogenic mutations, R201C, R201H
  • GPC3
    Protein expression
  • Globo H
    Expression
  • I
  • IDH1
    Oncogenic mutation, Oncogenic mutations, R119P, G131A, R132, R132C, R132C+D279N, R132G, R132H, R132L, R132S, D279N, S280F, G289D, H315D
  • IDH2
    Oncogenic mutation, Oncogenic mutations, R140, R140Q, R172, R172G, R172K, R172M, R172S, R172T, R172W, V305M
  • IRS2
    Amplification, Protein expression
  • IRS2+BRAF
    IRS2:Amplification AND BRAF:V600E
  • IRS2+KRAS
    IRS2:Amplification AND KRAS:G13D
  • Immunoscore IC
    High
  • Intrinsic subtype
    Basal-like, HER2-enriched, Luminal A, Luminal B, Normal-like
  • J
  • JAK1
    deletion, F958C, F958V, P960, Loss-of-function mutations
  • JAK2
    PCM1-JAK2 fusion, deletion, V617F, Y931C, Y931C and V617F, Loss-of-function mutations
  • K
  • KAT6A
    Amplification, Overexpression
  • KDM6A
    Oncogenic mutations, Loss-of-function mutations
  • KEAP1
    Oncogenic mutations
  • KEAP1+KRAS
    KRAS:G12C AND NOT KEAP1:Oncogenic mutations
  • KIT (CD117)
    NOT oncogenic mutations, Oncogenic mutations, Oncogenic mutations and NOT Amplification, Oncogenic mutations and NOT Amplification and NOT Exon 17 mutation, Exon 9 mutation, Exon 9 mutations, Exon 11 deletion, Exon 11 mutation, Exon 11 mutation and Exon 13 mutation, Exon 11 mutation and Exon 14 mutation, Exon 11 mutation and Exon 17 mutation, Exon 11 mutation and Exon 18 mutation, Exon 11 mutations, Exon 13 mutation, Exon 17 mutation, Exon 17 mutations, Amplification, Exon11 deletion, A502_Y503dup, A502_Y503dup and N822K, Y553N, D557, K558_G565delinsR, V559A, V559C, V559D, V559G, V560D, V560D and V654A, V560D and and V670I, V560G, V560_Y578del, V560del, L576P, P577_Y579del, K624E, Y627C, K642E, V654A, V654A and A829P, V654A and D816A, V654A and D820A, V654A and N822K, N655K, N655S, V669D, T670A, T670I, T670V, Y672C, D677N, N680K, F681L, R796G, C809G, D816, D816A, D816E, D816F, D816G, D816H, D816I, D816V, D816Y, I817L, D820A, D820E, D820G, D820N, D820V, D820Y, N822H, N822I, N822K, N822T, N822Y, Y823D, A829P, S840N, D842V, Overexpression, Protein expression
  • KLHL6
    Protein expression
  • KMT2A
    Rearrangement
  • KMT2C
    deletion, Loss-of-function mutations
  • KRAS
    KRAS:Oncogenic mutations + CDH1:Protein expression + VIM:NOT Protein expresssion, NOT KRAS:oncogenic mutation, NOT oncogenic mutations, Oncogenic mutation, Oncogenic mutation AND NOT G12C, Oncogenic mutations, Exon 3 insertion, Amplification, Amplification and NOT missense variant, G12C AND Amplification, V8L, V9F, A11_G12delinsGD, G12, G12A, G12C, G12D, G12F, G12R, G12S, G12V, G12W, G13C, G13D, G13V, V14I, V14L, K16T, L19F, Q22K, D33E, A59S, A59T, G60_A66dup, Q61E, Q61H, Q61K, Q61L, Q61P, Q61R, E62D, E62_A66dup, Y64N, R68S, M72L, G77V, H95D, H95N, H95Q, H95R, Y96C, Y96D, Y96H, Y96N, Q99K, Q99L, K117N, D119H, P121H, A146P, A146T, A146V, R149C, Switch 2 duplication
  • KRAS+ERBB3
    KRAS:Oncogenic mutations and ERBB3:Overexpression
  • KRAS+MET
    MET:exon 14 skipping mutation and KRAS:Oncogenic mutations
  • KRAS+Microsatellite Instability
    KRAS:Oncogenic mutations AND Microsatellite Instability:High
  • KRAS+Mismatch repair
    KRAS:Oncogenic mutations AND Mismatch repair:deficient
  • KRAS+NRAS
    NOT KRAS:exon 2 mutation and NOT KRAS:exon 3 mutation and NOT KRAS:exon 4 mutation and NOT NRAS:exon 2 mutation and NOT NRAS:exon 3 mutation and NOT NRAS:exon 4 mutation
  • KRAS+NRAS+BRAF
    NOT KRAS:Oncogenic mutation and NOT NRAS:Oncogenic mutation and NOT BRAF:Oncogenic mutation
  • KRAS+STK11
    KRAS:G12C and STK11:Oncogenic mutations
  • KRAS+TP53
    KRAS:Oncogenic mutations and NOT TP53:Alteration
  • L
  • LGALS1
    Protein expression
  • LRP1B
    Oncogenic mutations, Deletions, Loss-of-function mutations, Truncating mutations
  • LTK
    CLIP1-LTK fusion, I565N, F568C, L590M, L592F, G596R, D597N, L650F, G663A
  • LZTR1
    Loss-of-function mutations
  • Loss-of-heterozygosity score
    High
  • M
  • MAP2K1
    Oncogenic mutations, Negative regulatory domain deletion, F53L, Q56P, Q56_V60del, K57N, K57T, K57_G61del, L98_K104delinsQ, I99_K104del, E102_I103del, P105_107del, C121S, P124L, P124Q, P142L, E203K, K757E
  • MAP2K1+BRAF
    MAP2K1:P124 and BRAF:V600
  • MAP2K2
    Oncogenic mutations, V35M, L46F, Q60P, C125S, N126D, Y134H
  • MAP2K4
    Oncogenic mutations
  • MAP3K1
    Oncogenic mutations
  • MAP3K1+PIK3CA
    MAP3K1:Oncogenic mutations AND PIK3CA:Oncogenic mutations
  • MAPK1 (ERK2)
    Y36H, Y36N, P58L, P58S, P58T, Y64N, C65Y, Y131F, A189V, S202P, D321G, D321N, E322K
  • MAPK3 (ERK1)
    Y53H, G54A, S74G, P75L, Y81C, C82Y, R84H, Q90R, Y148H, G186D, A206V, S219P
  • MCL1
    Amplification
  • MDM2
    Amplification, Overexpression
  • MDM2+TP53
    MDM2:Amplification AND NOT TP53:Oncogenic mutations
  • MDM2+TP53+IDH1
    MDM2:Amplification AND NOT TP53:Oncogenic mutations AND NOT IDH1:Oncogenic mutations
  • MET
    CAV1-MET fusion, CD74-MET fusion, Fusions, PTPRZ-MET fusion, PTPRZ1-MET fusion, TFG-MET fusion, Oncogenic mutation, Oncogenic mutations, Exon 14 Deletion, Exon 14 skipping mutation, Exon 14 splicing mutation, Exon 16 mutation, Amplification, S244fs, N375S, Y1003 (Y1021), Y1003S (Y1021S), F1007fs (F1025fs), D1010 (D1028), Y1021H (Y1003H), D1028H (D1010H), D1028N (D1010N), V1092I, H1094Y, H1094Y (H1112Y), N1100S, H1106D, G1163, G1163 (G1181), G1163R (G1181R), R1170Q, L1195V, L1195V (L1213V), F1200I, F1200I (F1218I), D1228, D1228 (D1246), D1228A (D1246A), D1228H (D1246H), D1228H (D1246N), D1228N, D1228N (D1246N), Y1230 (Y1248), Y1230C (Y1248C), Y1230H, Y1230H (Y1248A), Y1230H (Y1248H), Y1230S (Y1248S), D1246 (D1228), D1246N (D1228N), Y1248 (Y1230), Y1248H (Y1230H), M1250T, K1262R (K1244R), A, Alteration, Alterations, C, C.2888-27_2888-2delinsC, G, No protein expression, Overexpression, Protein expression, T, c.2888-14_2888-4del, c.2888-17_2888-6del c.2888-18_2888-9del, c.2888-20_2888-11del, c.2888-5_2944del, c.2935_2939del, c.3028+1G>, c.3028+2T>, c.3028+3A>, c.3028G>, c.3280C>
  • MET+KRAS
    MET:Amplification and KRAS:G12V
  • MET+TP53
    MET:Exon 14 skipping mutation and TP53:Oncogenic mutations
  • MGMT
    Loss of protein expression, Loss-of-function mutations, Low protein expression, Methylation, Promoter methylation, Unmethylated
  • MLH1
    Loss of protein expression, Loss-of-function mutations
  • MRAS
    Q71R
  • MRE11A
    Oncogenic mutations (germline), L169Rfs*14, Loss-of-function mutations
  • MSH2
    R359S (germline), Loss of protein expression, Loss-of-function mutations
  • MSH6
    Loss-of-function mutations
  • MSLN
    Overexpression, Protein expression
  • MTAP
    deletion, Loss of protein expression
  • MTOR
    Oncogenic mutations, L1460P, E2014K, F2108L, L2209V, Q2223K, E2419K, L2427Q
  • MTORC1
    Oncogenic mutations
  • MUC1
    Protein expression
  • MYB
    MYB-NFIB fusion, Alteration, Overexpression
  • MYC
    Oncogenic mutations, Amplification, Overexpression
  • MYCL
    Amplification, Overexpression
  • MYCN
    Oncogenic mutations, Amplification, Overexpression
  • MYD88
    Oncogenic mutations, M232T, S243N, L265P, Gain-of-function mutations
  • Microsatellite Instability (MSI)
    High, Stable
  • Microsatellite instability+Mismatch repair
    NOT Microsatellite instability:high AND NOT Mismatch repair:deficient
  • Mismatch repair (MMR)
    Deficient, High, NOT Deficient, Proficient
  • Molecular subtype
    BLIA molecular subtype
  • Mutational signature
    SBS3 signature
  • N
  • NBN
    Oncogenic mutations
  • NECTIN4
    Amplification, Protein expression
  • NF1
    Oncogenic mutations, Oncogenic mutations (germline), deletion, N184fs, Q1336*, R2637*, Loss-of-function mutations
  • NF1+KIT
    NF1:Oncogenic mutations AND NOT KIT:Oncogenic mutations
  • NF1+MET
    NF1:Oncogenic mutation AND MET:Amplification, NF1:Deletion AND MET:Amplification
  • NF1+SUZ12
    NF1:deletion AND SUZ12:deletion, NF1:Loss-of-function mutations AND SUZ12:Loss-of-function mutations
  • NF2
    Oncogenic mutations, Oncogenic mutations (germline), deletion, Loss-of-function mutations, Truncating mutations
  • NOTCH1
    Oncogenic mutations, R2327fs*, Alterations, Overexpression
  • NOTCH2
    Gain-of-function mutations, Rearrangements
  • NOTCH3
    Overexpression
  • NRAS
    Oncogenic mutation, Oncogenic mutations, Amplification, G12, G12C, G12D, G12S, G13, G13D, G13R, G13V, Q61, Q61H, Q61K, Q61L, Q61R, Q61S, L95H
  • NRG1
    APP-NRG1 fusion, ATP1B1-NRG1 fusion, CD74-NRG1 fusion, CDH1-NRG1 fusion, CLU-NRG1 fusion, DOC4-NRG1 fusion, Fusion, Fusions, ITGB1-NRG1 fusion, POMK-NRG1 fusion, RBPMS-NRG1 fusion, SDC4-NRG1 fusion, SLC3A2-NRG1 fusion, VAMP2-NRG1 fusion, VTCN1-NRG1 fusion, High mRNA expression, Overexpression
  • NTRK1
    ARHGEF2-NTRK2 fusion, ATP1A4-NTRK1 fusion, Alterations AND NOT fusion, CD74-NTRK1 fusion, CDC42BPA-NTRK1 fusion, CGN-NTRK1 fusion, CGN-NTRK2 fusion, CTRC-NTRK1 fusion, DDR2-NTRK1 fusion, DIAPH1-NTRK1 fusion, EPS15-NTRK1 fusion, EPS15L1-NTRK1 fusion, ERC1-NTRK1 fusion, Fusion, Fusions, GON4L-NTRK1 fusion, IRF2BP2-NTRK1 fusion, IRF2BP2-NTRK2 fusion, KIF21B-NTRK2 fusion, KIRREL-NTRK2 fusion, LMNA-NTRK1 fusion, LMNA-NTRK2 fusion, MEF2D-NTRK2 fusion, NFASC-NTRK1 fusion, PDE4DIP-NTRK1 fusion, PDIA3-NTRK1 fusion, PDP0E4IP-NTRK2 fusion, PEAR1- NTRK1 fusion, PLEKHA6-NTRK1 fusion, PPL-NTRK1 fusion, SQSTM1-NTRK1 fusion, TPM3-NTRK1 fusion, TPM3-NTRK2 fusion, TPR-NTRK1 fusion, TPR-NTRK2 fusion, TRIM33-NTRK1 fusion, TRIM63-NTRK1 fusion, Amplification, V573M, F589L, G595R, A608D, G667A, G667C, G667S, High mRNA expression
  • NTRK2
    ABI2-NTRK2 fusion, AGAP1-NTRK2 fusion, ATP6V1A-NTRK2 fusion, Alterations AND NOT fusion, BEND5-NTRK2 fusion, C1orf112-NTRK2 fusion, CCDC88A-NTRK2 fusion, CHAMP1-NTRK2 fusion, CYP2E1-NTRK2 fusion, DENND5A-NTRK2 fusion, DNM3-NTRK2 fusion, ETV6-NTRK2 fusion, Fusion, Fusions, GKAP1-NTRK2 fusion, GNAI1-NTRK2 fusion, GNAQ-NTRK2 fusion, KANK1-NTRK2 fusion, KANK2-NTRK2 fusion, KCTD16-NTRK2 fusion, KCTD8-NTRK2 fusion, NACC2-NTRK2 fusion, PAPPA-NTRK2 fusion, PHF20L1-NTRK2 fusion, QKI-NTRK2 fusion, RBPMS-NTRK2 fusion, SBF2-NTRK2 fusion, SHANK1-NTRK2 fusion, SORBS1-NTRK2 fusion, SOS1-NTRK2 fusion, SPEC1L-NTRK2 fusion, SQSTM1-NTRK2 fusion, STMN1-NTRK2 fusion, STRN-NTRK2 fusion, TLE1-NTRK2 fusion, TRAF2-NTRK2 fusion, UGDH-NTRK2 fusion, VAMP4-NTRK2 fusion, Q596E, Q596P, G623S, F633L, G639R, V689M, G709C, High mRNA expression
  • NTRK3
    AKAP13-NTRK3 fusion, ARNT2-NTRK3 fusion, Alterations AND NOT fusion, BCR-NTRK3 fusion, EGR3-NTRK3 fusion, EML4-NTRK3 fusion, ETV6-NTRK3 fusion, FAM19A2-NTRK3 fusion, FOXJ2-NTRK3 fusion, Fusion, Fusions, IQGAP1-NTRK3 fusion, KANK1-NTRK3 fusion, KIF7-NTRK3 fusion, MN1-NTRK3 fusion, MYO5A-NTRK3 fusion, RBPMS-NTRK3 fusion, SOX6-NTRK3 fusion, SPEC1L-NTRK3 fusion, SPECC1L-NTRK3 fusion, SQSTM1-NTRK3 fusion, TFG-NTRK3 fusion, TPM4-NTRK3 fusion, F617C, F617I, F617L, G623E, G623R, G696A, G696C, High mRNA expression, Protein expression
  • NUTM1
    Protein expression
  • P
  • PALB2
    Oncogenic mutations, Oncogenic mutations (germline), Loss-of-function mutations, Loss-of-function mutations (germline), Reversion mutations
  • PAXIP1
    Oncogenic mutations
  • PBRM1
    Oncogenic mutations, Loss of protein expression, Loss-of-function mutations, Truncating mutations
  • PDCD1LG2
    Amplification
  • PDGFB
    COL1A1-PDGFB Fusion
  • PDGFRA
    FIP1L1-PDGFR fusion, FIP1L1-PDGFRA Fusion, FIP1L1-PDGFRA fusion and T674I, Fusion, Oncogenic mutations, Exon 12 mutation, Exon 14 mutation, Exon 18 deletion, Exon 18 mutation, Amplification, V516D, W559_R560del, R560del, V561D, P567P, N659K, T674I, D842V, D842V and T674R, D842V and V654A, D842Y, D842_H845del, D842_I843delinsIM, D842del, I843_D846del, I843_H846del, I843del, Overexpression, Protein expression
  • PDGFRB
    Fusions
  • PGR
    Protein expression
  • PIK3CA
    Oncogenic mutation, Oncogenic mutations, Amplification, R88Q, G118D, N345K, N345T, C420R, E453K, E542, E542K, E542K and E453, E542K and E726K, E542K and M1043, E543Q and H1047R, E545, E545A, E545D, E545G, E545K, E545K and E453, E545K and E726, Q546, Q546E, Q546R, Q546X, E726, E726K and H1047R, M1043, M1043I, H1047, H1047L, H1047R, H1047R and E453, H1047R and E726K, H1047Y, G1049R, H1074R, Helical domain mutation, Kinase domain mutation, Kinase domain mutations
  • PIK3CA+ESR1 (ER)+ERBB2 (HER2)
    PIK3CA:Oncogenic mutations and ESR1:protein expression and NOT ERBB2:amplification and NOT ERBB2:overexpression
  • PIK3CA+FGFR1
    PIK3CA:Oncogenic mutation AND FGFR1:Alteration
  • PIK3CA+FGFR2
    PIK3CA:Oncogenic mutation AND FGFR2:Alteration
  • PIK3R1
    Oncogenic mutation, Oncogenic mutations, deletion, S361fs
  • PIK3R2
    G373R
  • PMS2
    K706Sfs, Loss-of-function mutations
  • POLD1
    Oncogenic mutations, D402N, L606M, Loss of protein expression
  • POLE
    Oncogenic mutations, P286R, S297F, S297Y, T323A, F367S, V411L, L424I, P436R, A456P, S459F
  • POU2F3
    Protein expression
  • PPM1D
    Loss-of-function mutations
  • PPP2R2A
    Oncogenic mutations
  • PRKCA
    Fusion
  • PRKCB
    Fusion
  • PRKDC
    Oncogenic mutations, Loss-of-function mutations
  • PSMA
    Protein expression
  • PTCH1
    Oncogenic mutations, Loss-of-function mutations, Truncating mutations
  • PTEN
    Oncogenic mutations, Deletions, deletion, N48K, G209V, Alteration, Loss of protein expression, Loss-of-function mutations
  • PTEN+ERBB2 (HER2)
    PTEN:Loss of protein expression and ERBB2:amplification
  • PTPN11
    Oncogenic mutations, D61V, E72K, E76K, E76V, P491Q, Loss-of-function mutations
  • R
  • RAC1
    P29S
  • RAD21
    Oncogenic mutations
  • RAD50
    Oncogenic mutation, Oncogenic mutations, Deletions, Loss-of-function mutations
  • RAD51
    Loss of protein expression, Low protein expression
  • RAD51B
    Oncogenic mutations
  • RAD51C
    Oncogenic mutations, Oncogenic mutations (germline), Loss of promoter methylation, Loss-of-function mutations, Low protein expression, No protein expression, Promoter methylation
  • RAD51D
    Oncogenic mutations
  • RAD54L
    Oncogenic mutations
  • RAF1
    ANO10-RAF1 fusion, ATG7-RAF1 fusion, FYCO1-RAF1 fusion, Fusion, Fusions, GATM-RAF1 fusion, GOLGA4-RAF1 fusion, NFIA-RAF1 fusion, QKI-RAF1 fusion, RAF1-CCDC176 fusion, RAF1-TRAK1 fusion, SRGAP3-RAF1 fusion, Oncogenic mutations, K106N, S257P, P261L, P261T, G356E, G361A, S427T, D447N, M469I, E478K, R554K
  • RASA1
    Oncogenic mutations, Loss-of-function mutations
  • RB1
    Oncogenic mutation, Oncogenic mutations, Heterozygous deletion, deletion, Copy number loss, Loss of protein expression, Loss-of-function mutation, Loss-of-function mutations
  • RBM10
    Loss-of-function mutations
  • RET
    ARHGAP12-RET fusion, CCDC186-RET fusion, CCDC6-REF fusion, CCDC6-RET fusion, CCDC88C-RET fusion, CLIP1-RET fusion, DOCK1-RET fusion, ERC1-RET fusion, Fusion, Fusions, KIAA1468-RET fusion, KIAA1549L-RET fusion, KIF13A-RET fusion, KIF5B-RET fusion, KTN1-RET fusion, NCOA4-RET fusion, PRKAR1A-RET fusion, RBPMS-RET fusion, RELCH-RET fusion, RET fusions and NOT KIF5B-RET fusion, RUFY3-RET fusion, TRIM24-RET fusion, TRIM33-RET fusion, Oncogenic mutations, Oncogenic mutations (germline), Oncogenic mutations and NOT Amplification, Exon 10 deletion, D378_G385delinsE, V591_607del, C609, C611, C618, C620, C630, D631_L633delinsE, D631_L633delinsV, E632_L633del, C634, T636_V637insCRT, K666N, V738A, I788N, L790F, G801S, V804L, V804M, Y806C, Y806N, G810A, G810C, G810R, G810S, A883F, D898_E901del, D903_S904delinsEP, S904F, M918T, Cysteine rich domain mutation, Rearrangement
  • RICTOR
    Amplification
  • RIF1
    Oncogenic mutations
  • RIT1
    P128L
  • RNF43
    Oncogenic mutations, deletion, R371fs, G659fs, P660fs, C-terminal truncating mutations, Frameshift mutations, Loss-of-function mutations, Truncating mutations
  • ROS1
    CD74-ROS1 fusion, CD83-ROS1 fusion, CEP85L-ROS1 fusion, EZR-ROS1 fusion, Fusion, Fusions, GOPC-ROS1 Fusion, KLHDC2-ROS1 fusion. SLC34A2-ROS1 fusion, LRIG1-ROS1 fusion, MYH9-ROS1 fusion, SDC4-ROS1 fusion, SLC12A2-ROS1 fusion, SLC34A2-ROS1 fusion, SLC4A4-ROS1 fusion, TPM3-ROS1 fusion, TPR-ROS1 fusion, Amplification, E1395G, L1947R, L1951R, G1971E, S1986F, S1986Y, F2004C, L2026M, G2032R, D2033N, S2060G, F2075V, V2098U, G2101A, D2113G, L2155S
  • ROS1+MET
    ROS1:fusion AND MET:D1228N
  • RSPO1
    Fusion
  • S
  • SDHA
    Oncogenic mutation, Oncogenic mutations (germline)
  • SDHB
    Oncogenic mutation, Oncogenic mutations (germline)
  • SDHC
    Oncogenic mutation
  • SDHD
    Oncogenic mutation
  • SETD2
    Oncogenic mutations, Truncating mutations
  • SEZ6
    Protein expression
  • SF3B1
    Oncogenic mutations, R625C, R625H, R625L, H662Q, K700E
  • SLAMF7
    Protein expression
  • SLC1A5
    Overexpression
  • SLC39A6
    Protein expression
  • SLX4
    Loss-of-function mutations
  • SMARCA2
    Loss-of-function mutations
  • SMARCA2+SMARCA4
    SMARCA2:Loss of protein expression and SMARCA4:Loss of protein expression
  • SMARCA4
    Oncogenic mutations, Loss of protein expression, Loss-of-function mutations
  • SMARCB1
    Oncogenic mutations, deletion, Loss of protein expression
  • SMC3
    Oncogenic mutations
  • SMO
    Oncogenic mutations, R168H, E181K, R199Q, N219D, L221P, N223D, L225R, T241M, V281C, W281L, V321M, A327P, T336I, T349I, T349P, L353F, D384N, V386A, S387N, D388N, C390R, S391N, V404M, I408V, L412F, V414A, G453D, G457S, A459V, D473, D473G, D473H, D473Y, N476K, D477G, Q477E, E481G, G497W, D506N, P513L, E518, E518K, K519R, E522K, T534I, W535L, T548I, K564E, T640A, P641A, P698T, P739L, P739S
  • SPEN
    Oncogenic mutations
  • SRSF2
    Oncogenic mutations, P95H
  • SS18
    SS18-SSX fusion
  • SSTR2
    Protein expression
  • STAG2
    Oncogenic mutations
  • STEAP1
    Protein expression
  • STK11
    Oncogenic mutations
  • STK11+KRAS
    STK11:Oncogenic mutations AND KRAS:Oncogenic mutations
  • SUFU
    Loss-of-function mutations
  • SUZ12
    Loss-of-function mutations
  • V
  • VCTN1 (B7-H4)
    Protein expression
  • VHL
    Oncogenic mutations, Oncogenic mutations (germline)
  • W
  • WT1
    EWSR1-WT1 fusion, Loss-of-function mutations
  • WWTR1
    Fusion, WWTR1-CAMTA1 fusion (TAZ-CAMTA1 fusion)
  • X
  • XPO1
    C528S
  • XRCC2
    Loss-of-function mutations
  • Y
  • YAP1
    Fusion, YAP1-TFE3 fusion